2023
DOI: 10.1016/j.talanta.2022.124102
|View full text |Cite
|
Sign up to set email alerts
|

Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(5 citation statements)
references
References 52 publications
0
4
0
1
Order By: Relevance
“… 98 These nitrosyl compounds have potential carcinogenic, teratogenic, and mutagenic effects on the human body. 99 The European Food Safety Authority (EFSA) has set the Acceptable Daily Intake (ADI) for nitrates and nitrites at 3.7 mg and 0.07 mg per kilogram of body weight, respectively. 100 , 101 Similar to other clinical pharmacotherapies, nitrates have a specific dose-response range that defines their pharmacological activity.…”
Section: Methodsmentioning
confidence: 99%
“… 98 These nitrosyl compounds have potential carcinogenic, teratogenic, and mutagenic effects on the human body. 99 The European Food Safety Authority (EFSA) has set the Acceptable Daily Intake (ADI) for nitrates and nitrites at 3.7 mg and 0.07 mg per kilogram of body weight, respectively. 100 , 101 Similar to other clinical pharmacotherapies, nitrates have a specific dose-response range that defines their pharmacological activity.…”
Section: Methodsmentioning
confidence: 99%
“…Despite the aforementioned benefits of CDDS, concerns have been raised about the quality of some CR generic medications [13,14]. This has led to several recalls, including Pharmaceuticals 2024, 17, 271 2 of 15 orphenadrine citrate CR tablets [13], propoxyphene CR capsules [14], fentanyl HCL CR tablets [15], and dronabinol CR capsules [16]. The reasons behind these recalls remain ambiguous for some medications.…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, the presence of a carcinogenic impurity in pharmaceuticals, exemplified by N-nitrosodimethylamine, has raised significant public concerns [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. Carcinogenic impurities can potentially form during the production and storage of active pharmaceutical ingredients (APIs) and drug products [18].…”
Section: Introductionmentioning
confidence: 99%